Abstract
With the advance of aging, Alzheimer's disease (AD) is creating unsustainable challenges to healthcare and economy in China and worldwide. Recent researches demonstrated that the mechanism of AD involves a multiple of metabolic disorders, i.e. metallostasis, insulin resistance, neuroinflammation, alteration of mitochondria, and changes of blood brain barrier (BBB) function, linked with each other in the core mechanism of amyloid plaque and neurobrillary tangles (NFT). Strong evidences indicated that each of the major protein participants in AD pathology has physiologically important interactions with transition metals. The amyloid pathology causes disorders of metal homeostasis in neurons, which inversely aggravate AD progress. Metal-based drugs/agents are of great potential in AD diagnosis and therapy, i.e. (ⅰ) probes for early AD diagnosis, (ⅱ) metal ligands and/or complexes modulating metallostasis, (ⅲ) anti-diabetic metal complexes, and (ⅳ) BBB and neuron protective metal compounds.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
